Q-omics provides the consensus-scored LCOR profile across patient tissues and cancer cell-line models. LCOR expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LCOR is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, LCOR RNA expression shows 21,909 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LUAD as cancer lineages where LCOR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LCOR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LCOR survival associations across molecular data types. LCOR RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LCOR RNA expression–survival associations across cancer types. High LCOR expression shows unfavorable associations in ACC, UVM and LIHC, but favorable associations in KIRC, SCLC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LCOR RNA expression.
This table summarizes LCOR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LCOR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LCOR shows lower tumor expression in KICH and higher tumor expression in LUAD, STAD, LUSC, LIHC and BLCA. The LUAD box plot shows higher LCOR RNA expression in tumor versus normal tissue (log2 FC = +1.211, t-test p < 0.001).
This table shows molecular features associated with LCOR in patient tissues and cancer cell lines. In patient samples, LCOR shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LCOR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
